SDPA Conference Abstracts & Posters - JDPA

Journal of Dermatology for Physician Assistants

The official journal of the Society of Dermatology Physician Assistants

SDPA Abstracts & Posters

Fall 2022--Miami, Florida

#01-Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Phase 3 Trial

#02-Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: A Post-hoc Analysis of Phase 3 Trials

#03-Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a 24-52-week, Open-label Phase 2 Trial

#04-Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States

#05-Improving Patient Selection for Adjuvant Therapy: Considerations for the Role of the 31-gene Expression Profile

#06-Demodex Mites in Patients with Non-melanoma Skin Cancer

#07-Validation of a Handheld Elastic-scattering Spectroscopy Device on Lesions Suggestive of Melanoma

#08-Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

#09-Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

#10-Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

#11-Efficacy of Spesolimab for Generalized Pustular Psoriasis (GPP) Flare Treatment According to GPP Area and Severity Index (GPPASI) Score at Baseline

#12-Effects of Ruxolitinib Cream on Patient-Reported Quality of Life in Atopic Dermatitis: 52-Week Pooled Results from Two Phase 3 Studies

#13-High-threshold Responses to Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

#14-Clinically Meaningful Responses Achieved with Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis Who Did Not Meet IGA 0/1 at Initial 16-week Treatment

#15-Long-term Improvements in Disease Severity, Itch, and Quality of Life after 3 Years of Tralokinumab Treatment in Adults with Moderate-to-severe Atopic Dermatitis

#16-Safety of Tralokinumab in Pediatric Patients Aged 12–17 with Moderate-to-severe Atopic Dermatitis: Results from the Phase 3 ECZTRA 6 Trial

#17-The Impact of Tralokinumab on Quality of Life and School in Patients Aged 12–17 with Atopic Dermatitis: Results from the Phase 3 ECZTRA 6 Trial

#18-Skin Cancer Awareness Grant (SCAN)

#19-Brodalumab: 4-Year US Pharmacovigilance Report

#20-Efficacy of Brodalumab vs Ustekinumab by Prior TNF-α Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies

#21-Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Decreases TNF-α Levels within Psoriatic Lesions

#22-Long-term Efficacy and Safety in Participants Who Achieved Skin Clearance in an Open-label Study of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion

#23-Onychomycosis Dermatophytoma Treatment: A Systematic Review of the Literature

#24-Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability

#25-Efficacy and Safety of Abrocitinib Monotherapy in Adults and Adolescents with Moderate to Severe Atopic Dermatitis: A Post-hoc Analysis of JADE Regimen

#26-Once-Daily Crisaborole as a Long-Term Maintenance Treatment in Patients with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Trial

#27-Dupilumab Ameliorates Sleep Disturbance and Relieves Itch in Adults with Moderate-to-severe Atopic Dermatitis Over 24 Weeks

#28-Dupilumab Significantly Improves Itch and Skin Lesions in Patients with Prurigo Nodularis: Results from a 2nd Phase 3 Trial (LIBERTY-PN PRIME)

#29-Dupilumab Treatment Normalizes Skin Barrier Function and Improves Clinical Outcomes in Patients with Atopic Dermatitis

#30-Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

#31-Improvement in Disease Severity and Quality of Life in Patients with Atopic Dermatitis (AD) Treated With Dupilumab for up to 18 Months: Real-World Evidence From the PROSE Registry

#32-Long-Term Efficacy of Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis (AD): Results from an Open-Label Extension (OLE) Trial up to 4 years

#33-Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension (OLE) Trial up to 4 years

#34-A Multicenter Open-Label Trial Evaluating Efficacy and Tolerability of an Advanced Topical Antioxidant Containing Allyl Pyrroloquinoline Quinone in Subjects with Mild to Moderate Facial Photodamage

#35-Efficacy and Safety of 1% Clascoterone Cream through 12 Weeks in Patients ≥12 Years of Age with Facial Acne Vulgaris: Pooled Data Analyses of Two Phase 3 Randomized Clinical Trials

#36-Patients’ Quality of Life and Satisfaction with Treatment in a Phase 4 Real-world Study of Tildrakizumab in Moderate-to-severe Plaque Psoriasis

#37-Deucravacitinib in Plaque Psoriasis: 2-Year Laboratory Results from the Phase 3 POETYK PSO Program

#38. Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program

#39. Deucravacitinib Long-term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program

#40-Bimekizumab (BKZ) Efficacy in High-impact Areas for Patients (pts) with Moderate to Severe Plaque Psoriasis: Pooled Results through Two Years from the BE SURE and BE RADIANT Phase 3 Trials

#41-Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients With Moderate to Severe Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

#42-Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis

Abstracts also presented in JDPA digital edition

CME-Accredited Articles

Climate Change, Cutaneous Disease, and the Dermatology Provider

By Annika Belzer, BS, and Misha Rosenbach, MD ABSTRACT Climate change is a public health crisis with pervasive repercussions on health. The integumentary system faces

Basics in Mental Health Screening for Suicide Risk Assessment in Dermatology

By Catherine R. Judd, MS, PA-C, CAQ Psych, DFAAPA Catherine R. Judd, MS, PA-C, CAQ Psych, DFAAPA, is Clinical Adjunct Faculty at University of Texas

Chronic Pruritus: Etiologies, Pathophysiology, and Therapeutic Options

By Cristina M. Foschi, BS, and Peter Lio, MD, FAAD ABSTRACT The purpose of this article is to discuss the pathogenesis of itch along with

Hypopigmented Mycosis Fungoides in Younger Patients: A Mimicker of Common Hypopigmented Inflammatory Rashes

By Candice E. Macari, DMSc, MSPAS, MPH, PA-C